Payment overview · 2025
General Payments
$917.40
55 reported records · 16 companies
Healthcare provider profile · identity verified
Jay C. Proctor, MD
Allopathic & Osteopathic Physicians|Family Medicine · BEAUMONT, TX · NPI 1538160726
Verified facts
What the public records show
CMS Open Payments records show Jay C. Proctor, MD received $917.40 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nexletol, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.77 | 23.6% | 20 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.77 | 12.5% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $108.88 | 11.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.56 | 11.7% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $75.11 | 8.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.70 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.09 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.56 | 3.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.90 | 3.7% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.11 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.71 | 3.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.68 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.69 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.67 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $917.40 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.79 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $160.95 | 11 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $114.77 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $108.88 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $75.11 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.98 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 731 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 111 |
| Ezetimibe | Ezetimibe | 325 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 80 |
| Lisinopril | Lisinopril | 241 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 196 | 49 |
| Losartan Potassium | Losartan Potassium | 191 | 64 |
| Alprazolam | Alprazolam | 178 | 38 |
| Allopurinol | Allopurinol | 158 | 41 |
| Omeprazole | Omeprazole | 156 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 48 |
| Metformin Hcl Er | Metformin Hcl | 152 | 43 |
| Gabapentin | Gabapentin | 145 | 48 |
| Metformin Hcl | Metformin Hcl | 145 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 42 |
| Repatha Sureclick | Evolocumab | 140 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 47 |
| Synthroid | Levothyroxine Sodium | 111 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 27 |
| Farxiga | Dapagliflozin Propanediol | 107 | 30 |
| Clonazepam | Clonazepam | 102 | 27 |
| Montelukast Sodium | Montelukast Sodium | 96 | 32 |
| Meloxicam | Meloxicam | 92 | 38 |
| Bupropion Xl | Bupropion Hcl | 91 | 27 |
| Sertraline Hcl | Sertraline Hcl | 87 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 24 |
| Ozempic | Semaglutide | 86 | 20 |
| Glimepiride | Glimepiride | 82 | 25 |
| Simvastatin | Simvastatin | 80 | 27 |
| Mounjaro | Tirzepatide | 78 | 16 |
| Alendronate Sodium | Alendronate Sodium | 77 | 24 |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Jardiance | Empagliflozin | 74 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 19 |
| Furosemide | Furosemide | 68 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 18 |
| Tramadol Hcl | Tramadol Hcl | 56 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 49 | 13 |
| Pregabalin | Pregabalin | 49 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 13 |
| Carvedilol | Carvedilol | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Trulicity | Dulaglutide | 44 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 13 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Famotidine | Famotidine | 37 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 18 |
| Estradiol | Estradiol | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Valsartan | Valsartan | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Acarbose | Acarbose | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Diazepam | Diazepam | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $917.40 · 55 records | ABBVIE INC. | AREXVY, AUSTEDO XR, Auvelity, INSPIRE, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error